257 related articles for article (PubMed ID: 24603404)
21. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
[TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant chemoradiotherapy for advanced esophageal cancer].
Natsugoe S; Matsumoto M; Okumura H; Uchikado Y; Setoyama T; Kita Y; Arigami T; Uenosono Y; Owaki T; Ishigami S
Nihon Geka Gakkai Zasshi; 2011 Mar; 112(2):111-6. PubMed ID: 21488344
[TBL] [Abstract][Full Text] [Related]
23. [Squamous cell carcinoma of the oesophagus--impact of surgery within the therapeutic concept].
Gockel I; Lang H
Z Gastroenterol; 2010 May; 48(5):560-6. PubMed ID: 20449788
[TBL] [Abstract][Full Text] [Related]
24. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
Malaisrie SC; Untch B; Aranha GV; Mohideen N; Hantel A; Pickleman J
Arch Surg; 2004 May; 139(5):532-8; discussion 538-9. PubMed ID: 15136354
[TBL] [Abstract][Full Text] [Related]
26. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
van de Schoot L; Romme EA; van der Sangen MJ; Creemers GJ; van Lijnschoten G; van Driel OJ; Rutten HJ; Nieuwenhuijzen GA
Ann Surg Oncol; 2008 Jan; 15(1):88-95. PubMed ID: 17896144
[TBL] [Abstract][Full Text] [Related]
27. [Chemoradiotherapy followed by surgery in treatment of locally advanced esophageal carcinoma: a phase II trial].
Fu JH; Rong TH; Li XD; Hu Y; Ou W; Hu YH; Li Q
Ai Zheng; 2004 Nov; 23(11 Suppl):1473-6. PubMed ID: 15566661
[TBL] [Abstract][Full Text] [Related]
28. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
Markar SR; Bodnar A; Rosales J; Song G; Low DE
Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
[TBL] [Abstract][Full Text] [Related]
29. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
30. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
[TBL] [Abstract][Full Text] [Related]
31. Predicting response to neoadjuvant therapy in esophageal cancer.
Vallböhmer D; Brabender J; Grimminger P; Schröder W; Hölscher AH
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1449-55. PubMed ID: 21929318
[TBL] [Abstract][Full Text] [Related]
32. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
[TBL] [Abstract][Full Text] [Related]
33. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
34. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.
Porschen R; Fischbach W; Gockel I; Hollerbach S; Hölscher A; Jansen PL; Miehlke S; Pech O; Stahl M; Vanhoefer U; Ebert MPA
United European Gastroenterol J; 2024 Apr; 12(3):399-411. PubMed ID: 38284661
[TBL] [Abstract][Full Text] [Related]
35. [Current diagnosis and therapy of esophageal carcinoma].
Mühr-Wilkenshoff F; Stahl M; Faiss S; Zeitz M; Scherübl H
Z Gastroenterol; 2004 Jul; 42(7):615-21. PubMed ID: 15248111
[TBL] [Abstract][Full Text] [Related]
36. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
37. [Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].
Hölscher AH; Metzger R; Schneider PM
Zentralbl Chir; 2000; 125(4):319-25. PubMed ID: 10829311
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant therapy for esophageal cancer: surgical considerations.
Piraino A; Vita ML; Tessitore A; Cusumano G; Congedo MT; Margaritora S; Porziella V; Meacci E; Cesario A; Granone P
Rays; 2006; 31(1):37-45. PubMed ID: 16999374
[TBL] [Abstract][Full Text] [Related]
39. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
40. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]